{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ketorolac%2C+Nepafenac", "query": { "intervention": "Ketorolac, Nepafenac" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 9, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T16:04:15.987Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00333255", "title": "Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cataract" ], "interventions": [ { "name": "Nepafenac Ophthalmic Suspension, 0.1%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 267, "start_date": "2005-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-07-08", "last_synced_at": "2026-09-30T16:04:15.987Z", "location_count": 1, "location_summary": "Nacogdoches, Texas", "locations": [ { "city": "Nacogdoches", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00333255" }, { "nct_id": "NCT00332774", "title": "Nevanac 3-Month Safety Study With QID Dosing", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cataract" ], "interventions": [ { "name": "Nepafenac ophthalmic solution 0.1%", "type": "DRUG" }, { "name": "Ketorolac Tromethamine ophthalmic solution 0.4%", "type": "DRUG" }, { "name": "Nepafenac ophthalmic suspension vehicle", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 149, "start_date": "2006-02", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2012-03-05", "last_synced_at": "2026-09-30T16:04:15.987Z", "location_count": 1, "location_summary": "Fort Worth, Texas", "locations": [ { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00332774" }, { "nct_id": "NCT00330798", "title": "A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Photorefractive Keratectomy" ], "interventions": [ { "name": "nepafenac 0.1%", "type": "DRUG" }, { "name": "ketorolac 0.4%", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 40, "start_date": "2006-02", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2016-11-18", "last_synced_at": "2026-09-30T16:04:15.987Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00330798" }, { "nct_id": "NCT00377546", "title": "Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Vitrectomy" ], "interventions": [ { "name": "Nepafenac", "type": "DRUG" }, { "name": "Ketorolac LS, Bromfenac", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innovative Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2008-09-25", "last_synced_at": "2026-09-30T16:04:15.987Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00377546" }, { "nct_id": "NCT07276802", "title": "The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Post Cataract Surgery" ], "interventions": [ { "name": "Triamcinolone (Optional)", "type": "DRUG" }, { "name": "control group", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Research Insight LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 40, "start_date": "2026-04-01", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-09-30T16:04:15.987Z", "location_count": 1, "location_summary": "Laguna Hills, California", "locations": [ { "city": "Laguna Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07276802" }, { "nct_id": "NCT02752646", "title": "Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cataract" ], "interventions": [ { "name": "nepafenac 0.3%", "type": "DRUG" }, { "name": "ketorolac", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MDbackline, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 200, "start_date": "2016-04", "completion_date": "2017-03-01", "has_results": false, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-09-30T16:04:15.987Z", "location_count": 2, "location_summary": "Laguna Hills, California • Edgewood, Kentucky", "locations": [ { "city": "Laguna Hills", "state": "California" }, { "city": "Edgewood", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02752646" }, { "nct_id": "NCT00348582", "title": "Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cataract" ], "interventions": [ { "name": "Ketorolac, Nepafenac", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innovative Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2007-06-25", "last_synced_at": "2026-09-30T16:04:15.987Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00348582" }, { "nct_id": "NCT00407017", "title": "Therapeutic Variables in Cataract Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cataract Surgery" ], "interventions": [ { "name": "Gatifloxacin", "type": "DRUG" }, { "name": "Ketorolac LS", "type": "DRUG" }, { "name": "Pred Forte", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Nepafenac", "type": "DRUG" }, { "name": "EconoPred Plus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innovative Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2007-08-21", "last_synced_at": "2026-09-30T16:04:15.987Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00407017" }, { "nct_id": "NCT01001806", "title": "A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cataracts" ], "interventions": [ { "name": "Ketorolac Tromethamine 0.45%", "type": "DRUG" }, { "name": "bromfenac 0.09%", "type": "DRUG" }, { "name": "nepafenac 0.1%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Frank A. Bucci, Jr., M.D.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2009-10", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2011-10-03", "last_synced_at": "2026-09-30T16:04:15.987Z", "location_count": 1, "location_summary": "Wilkes-Barre, Pennsylvania", "locations": [ { "city": "Wilkes-Barre", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01001806" } ] }